Glutamate is the most abundant excitatory neurotransmitter in the central nervous system (CNS). It plays crucial roles in neurodevelopment, synaptic plasticity, and cognitive function [1]. Problems arising from dysregulated glutamate signaling are typically associated with various neuropsychiatric and neurodegenerative conditions, for example, schizophrenia, depression, epilepsy, and Alzheimer’s disease [2-4]. Medications targeting glutamate receptors and associated pathways are therefore important as therapeutic agents.
In today’s article, we will look at some of the main classes of drugs that affect glutamate levels and signaling, as well as their mechanisms, applications, and potential implications of their use.
How Does Glutamate Signaling Work?
Glutamate signaling has been studied extensively in healthy and diseased states. Glutamate interacts with two main glutamate receptor (GluR) types: ionotropic and metabotropic.
Ionotropic receptors mediate fast synaptic transmission and include the N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptor subfamilies.
Metabotropic GluRs, on the other hand, act via secondary messenger systems to modulate neuronal excitability. They are divided into eight subtypes (mGluR1 – 8) that influence neuronal signaling and synaptic plasticity.
The pharmacological modulation of these receptors presents an avenue for managing diseases associated with dysregulated glutamate signaling, for example, depression and other stress-related conditions [5].
NMDA Receptor Antagonists
NMDA receptors are critical for synaptic plasticity and memory function but can lead to excitotoxicity when overactivated. NMDA receptor antagonists can be categorized into competitive, non-competitive, and uncompetitive antagonists, each with a unique binding mechanism.
Ketamine was originally used as an anesthetic, and functions as an uncompetitive NMDA receptor antagonist, meaning it binds to an active receptor rather than competing with glutamate. At sub-anesthetic doses, ketamine has rapid antidepressant effects and has been used to address treatment-resistant depression. It has a swift yet fleeting action and there are still concerns about its potential for abuse and neurotoxicity with prolonged use. It has however been highlighted as a promising and novel medication for treating depressive disorders [6,7].
Like ketamine, memantine is an uncompetitive antagonist of NMDA receptors and has been primarily used to treat moderate to severe Alzheimer’s disease [8]. It is especially beneficial in reducing excitotoxicity without significant psychotropic side effects and unlike ketamine it does not bring about dissociative effects, making it more suitable for chronic use.
AMPA Receptor Modulators
AMPA receptors (AMPARs) support fast excitatory synaptic transmission. They play a key role in mediating the action of glutamate at the excitatory synapse [9]. Drugs that target AMPARs include both antagonists and positive allosteric modulators.
Perampanel is one such non-competitive AMPAR antagonist that is used as an anticonvulsant, mainly for partial-onset seizures and generalized seizures. By reducing AMPAR-mediated excitatory signaling, perampanel helps prevent hyperexcitability, a feature of seizure disorders. However, it has also been linked with psychiatric side effects including aggression and mood disturbances.
Kainate Receptor Modulators
Kainate receptors, though less understood than AMPARs and NMDARs, play a role in modulating synaptic plasticity and excitability, particularly in the hippocampus [10]. Kainate receptor antagonists, like topiramate, have been explored for their anticonvulsant properties.
Topiramate is primarily an AMPAR antagonist but also modulates kainate receptors and has gained widespread use as an anticonvulsant and mood stabilizer. Research has pointed to its use in the treatment of epilepsy, migraine headaches, bipolar disorder, eating disorders, and alcohol dependence [11]. Its broad mechanism, including effects on GABAergic transmission, contributes to its effectiveness but may also lead to impaired cognition and weight loss.
Metabotropic Glutamate Receptor Modulators
Metabotropic GluRs modulate a wide range of CNS functions, from neuroprotection to synaptic plasticity, by influencing intracellular signaling pathways. A wide range of these are being investigated for their potential in treating neuropsychiatric conditions [12], such as schizophrenia, addiction, major depressive disorder and anxiety, fragile X syndrome, Parkinson's disease, Alzheimer's disease, and pain.
Glutamate Release Inhibitors
Instead of targeting specific glutamate receptors, some drugs work by inhibiting glutamate release from presynaptic neurons. This approach may prevent excitotoxicity and reduce hyperexcitability in disorders like epilepsy.
Riluzole (2-amino-6-trigluoromethoxy benzothiazole) has neuroprotective, anticonvulsant, anxiolytic, and anesthetic qualities [13]. These effects are mediated by the blockade of glutamate transmission, the stabilizing of sodium channels, and the blockade of gamma-aminobutyric acid (GABA) reuptake. The action profile of riluzole is dominated by its effects on glutamate transmission which are predominately mediated by NMDA receptor-linked processes in vitro. It is approved for the treatment of amyotrophic lateral sclerosis (ALS) [14]. By limiting glutamate release, riluzole reduces excitotoxic damage to motor neurons, thereby slowing ALS progression. While its efficacy in other neurodegenerative diseases remains under investigation, its success in ALS highlights the potential of targeting presynaptic mechanisms in glutamatergic transmission.
Lamotrigine is an anticonvulsant and mood stabilizer used to treat epilepsy and bipolar disorder. It inhibits voltage-gated sodium channels, which indirectly reduces glutamate release. Despite its applications, the mechanism of action remains only partly understood. The broad effect of lamotrigine on glutamatergic transmission may account for its effectiveness in stabilizing mood [15].
Difficulties in Developing Glutamate-Based Drugs
While the modulation of glutamate signaling presents a promising therapeutic strategy, there are still challenges concerning drug development. The widespread distribution of glutamate receptors throughout the CNS means that drugs targeting these receptors can have unintended side effects, including cognitive impairment, mood disturbances, and psychotropic effects. In addition, many glutamate-targeting drugs have limited bioavailability and have difficulty crossing the blood-brain barrier, which complicates their therapeutic use. Advances in pharmacokinetics, targeted drug delivery, and allosteric modulation may overcome these limitations, leading to safer and more effective therapies [16].
Summary
In this article, we have examined a selection of drugs that affect glutamate signaling in various ways. Many agents have potential therapeutic applications in psychiatry, neurology, and neurodegeneration. Glutamate-targeting drugs represent a dynamic area of pharmacological research that still needs to be completely unraveled. Ongoing work aims to refine these treatments, limit side effects, and expand the options available for people with glutamate-associated disorders.
Curious about the relationship between GABA and glutamate? You can read more about their interplay and roles here.
References
[1] S.S. Willard, S. Koochekpour, Glutamate, Glutamate Receptors, and Downstream Signaling Pathways, Int. J. Biol. Sci. 9 (2013) 948–959. https://doi.org/10.7150/ijbs.6426.
[2] C. Soares, L.U. Da Ros, L.S. Machado, A. Rocha, G. Lazzarotto, G. Carello-Collar, M.A. De Bastiani, J.P. Ferrari-Souza, F.Z. Lussier, D.O. Souza, P. Rosa-Neto, T.A. Pascoal, B. Bellaver, E.R. Zimmer, The glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis, Mol Psychiatry 29 (2024) 2261–2273. https://doi.org/10.1038/s41380-024-02473-0.
[3] M.R. Hynd, H.L. Scott, P.R. Dodd, Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease, Neurochem Int 45 (2004) 583–595. https://doi.org/10.1016/j.neuint.2004.03.007.
[4] A. Kelly, C.A. Stanley, Disorders of glutamate metabolism, Ment. Retard. Dev. Disabil. Res. Rev. 7 (2001) 287–295. https://doi.org/10.1002/mrdd.1040.
[5] S. Dogra, P.J. Conn, Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders, Neuropharmacology 196 (2021) 108687. https://doi.org/10.1016/j.neuropharm.2021.108687.
[6] D.J. Newport, L.L. Carpenter, W.M. McDonald, J.B. Potash, M. Tohen, C.B. Nemeroff, APA Council of Research Task Force on Novel Biomarkers and Treatments, Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression, Am J Psychiatry 172 (2015) 950–966. https://doi.org/10.1176/appi.ajp.2015.15040465.
[7] R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, J.H. Krystal, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry 47 (2000) 351–354. https://doi.org/10.1016/s0006-3223(99)00230-9.
[8] S. Matsunaga, T. Kishi, N. Iwata, Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis, PLoS One 10 (2015) e0123289. https://doi.org/10.1371/journal.pone.0123289.
[9] H. Potschka, E. Trinka, Perampanel: Does it have broad‐spectrum potential?, Epilepsia 60 (2019) 22–36. https://doi.org/10.1111/epi.14456.
[10] X.-T. Jin, Y. Smith, Localization and Functions of Kainate Receptors in the Basal Ganglia, in: A. Rodríguez-Moreno, T.S. Sihra (Eds.), Kainate Receptors, Springer US, Boston, MA, 2011: pp. 27–37. https://doi.org/10.1007/978-1-4419-9557-5_3.
[11] C.M. Moore, M. Wardrop, B. deB Frederick, P.F. Renshaw, Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study, Psychopharmacology (Berl) 188 (2006) 236–243. https://doi.org/10.1007/s00213-006-0451-y.
[12] N. Hovelsø, F. Sotty, L.P. Montezinho, P.S. Pinheiro, K.F. Herrik, A. Mørk, Therapeutic potential of metabotropic glutamate receptor modulators, Curr Neuropharmacol 10 (2012) 12–48. https://doi.org/10.2174/157015912799362805.
[13] B.D. Kretschmer, U. Kratzer, W.J. Schmidt, Riluzole, a glutamate release inhibitor, and motor behavior, Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 181–190. https://doi.org/10.1007/pl00005241.
[14] J.A. Andrews, C.E. Jackson, T.D. Heiman-Patterson, P. Bettica, B.R. Brooks, E.P. Pioro, Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis, Amyotroph Lateral Scler Frontotemporal Degener 21 (2020) 509–518. https://doi.org/10.1080/21678421.2020.1771734.
[15] B. Costa, N. Vale, Understanding Lamotrigine’s Role in the CNS and Possible Future Evolution, IJMS 24 (2023) 6050. https://doi.org/10.3390/ijms24076050.
[16] D.C. Javitt, D. Schoepp, P.W. Kalivas, N.D. Volkow, C. Zarate, K. Merchant, M.F. Bear, D. Umbricht, M. Hajos, W.Z. Potter, C.-M. Lee, Translating Glutamate: From Pathophysiology to Treatment, Sci. Transl. Med. 3 (2011). https://doi.org/10.1126/scitranslmed.3002804.
Comments (0)
There are no comments for this article. Be the first one to leave a message!